Subscribe   RSS Contact Us

Kamp Commentary: Pricing Issues Take Center Stage in D.C.

May 23, 2017 — By Coalition for Healthcare Communication Executive Director John Kamp Participants at last week’s Coalition for Healthcare ... read more

Califf Calls for Off-label Promotion Code of Ethics

May 18, 2017 – At this week’s information-packed Coalition for Healthcare Communication’s Rising Leaders Conference, keynote speaker and former FDA ... read more

The Marketing Implications of Tax Reform

By John Kamp, Coalition for Healthcare Communication Executive Director May 11, 2017 – Although no one seems to like the ... read more

Gottlieb Vote Headed to Full Senate

May 1, 2017 – Having cleared the Senate Committee on Health, Education, Labor and Pensions (HELP) with a 14-9 vote ... read more

What Medical Marketers Can Expect from President Trump, Republican-led Congress

April 24, 2017 – There is no doubt that the Trump administration is likely to change health policy, but the ... read more

Kamp: Three Ways Congress Could Suppress DTC or All Medical Marketing

Coalition Commentary by Executive Director John Kamp April 17, 2017 — Agencies, media and clients all need to watch closely ... read more

States Make Moves to Ease, Restrict Medical Communications

March 31, 2017 – With Congress in a seemingly permanent state of gridlock, individual states are taking actions that may ... read more

Previous Next

The Debate Over Increased Transparency

From Tom Sullivan’s Policy and Medicine blog, July 16, 2010:

As drug companies “prepare for new draconian provisions for reporting on financial relationships with prednisone vs hydrocodone academia,” a recent article in Nature Biotechnology investigated whether such efforts to “increase transparency will prove burdensome to researchers and the industry.”

The inquiry stems from “the latest fallout from Senator Charles Grassley’s (R-IA) campaign for increased transparency between physician researchers and industry.” This campaign has included numerous letters and investigations involving doctors, organizations and associations, agencies (e.g. NIH), medical journals, and drug and device companies.

Read more on their website, then come back here to comment.generic viagra soft tabs

Comments are closed.